Chimeric antigen receptor T cell therapy - Diakonos Oncology
Latest Information Update: 06 Dec 2022
At a glance
- Originator Diakonos Research
- Developer Diakonos Oncology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical HER2 positive breast cancer; Solid tumours
Most Recent Events
- 25 Nov 2022 Diakonos Research announces intention to file IND to US FDA for HER2 positive breast cancer and solid tumours in 2024
- 25 Nov 2022 Preclinical trials in HER2-positive-breast-cancer in USA (Parenteral) (Diakonos Research pipeline, November 2022)
- 25 Nov 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Diakonos Oncology pipeline, November 2022)